Pantoprazole Sodium
Brand names: Protonix Iv, Pantoprazole Sodium, Protonix
At a glance
- Medicare prescriptions, 2024
- 24,181,424
- Medicare drug cost
- $306.8M
- Average cost per prescription
- $12.69
- Clinicians who prescribed it
- 296,871
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Pantoprazole sodium delayed-release tablets are indicated for: Pantoprazole sodium
From the FDA-approved prescribing information (label dated August 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Family Medicine 29.9%
- Internal Medicine 25.8%
- Nurse Practitioners 18.5%
- Gastroenterology 8.3%
- Physician Assistants 6.4%
- General Practice 1.8%
- Geriatric Medicine 1.6%
- Cardiology 1.3%
- Hospitalist 1.1%
- Nephrology (Kidney) 0.6%
- Pulmonology 0.6%
- General Surgery 0.5%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 39% from 2019 to 2024.
Biggest change by state since 2019
- Utah +60%
- Montana +58%
- Wyoming +55%
- Oklahoma +54%
- South Dakota +54%
- California (smallest change) +30%
- Maine (smallest change) +30%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 1 maker on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Redpharm Drug
| Strength | Looks like | Imprint |
|---|---|---|
| 40 mg | yellow oval tablet, 12 mm | I 52 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $4,250 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Pfizer Inc. $4,250
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
6 recalls since 2020
- Mar 2026 · Hetero Labs Limited (unit V) · Class II
Discoloration: Firm received five complaints stating that, "Tablets discolored darker than normal and have lighter-colored spots." - Sep 2023 · Be Pharmaceuticals AG · Class II
Lack of Assurance of Sterility: Powder discoloration due to small crack in some vials. - Mar 2023 · Hetero USA Inc · Class II
CGMP Deviations: Discoloration - Jul 2022 · Sun Pharmaceutical Industries Inc · Class II
Discoloration - Mar 2021 · Cardinal Health Inc. · Class II
CGMP Deviations: Intermittent exposure to temperature excursion during storage. - Feb 2021 · Sun Pharmaceutical Industries Inc · Class III
Failed Impurity/Degradation Specifications
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.